Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509

Investigative Ophthalmology and Visual Science

Volumn 37, Issue 6, 1996, Pages 1149-1156

  Robison Jr , W Gerald ^a   Laver, Nora M ^a,b   Jacot, Jorgel ^a   Glover, Joelp ^a   Basso, Michael D ^c   Blouin, Paule ^c   Hohman, Thomas C ^c  

^a NATIONAL EYE INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

aldose reductase; computer morphometry; diabetic retinopathy; galactose fed rat model; polyol pathway

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; GALACTITOL; GALACTOSE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; MINALRESTAT;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; GALACTOSEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; CATARACT; DIABETIC RETINOPATHY; ERYTHROCYTES; FEMALE; GALACTITOL; GALACTOSE; HEMOGLOBIN A, GLYCOSYLATED; IMAGE PROCESSING, COMPUTER-ASSISTED; LENS, CRYSTALLINE; POLYMERS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL VESSELS;

EID: 0029934820     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Frank RN, Keirn RJ, Kennedy A, Frank KW. Galactose-induced retinal capillary basement membrane thickening: Prevention by sorbinil. Invest Ophthalmol Vis Sci. 1983;24:1519-1524.
2. Robison WG Jr, Kador PF, Kinoshita JH. Retinal capillaries: Basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 1983;221:1177-1179.
3. Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci. 1989;30:2285-2292.
4. Robison WG Jr, Tillis TN, Laver N, Kinoshita JH. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res. 1990;50:355-366.
5. Robison WG Jr, Laver NM. Ocular lesions in animal models of human diabetes. In: Shafrir E, ed. Frontiers in Diabetes Research, Lessons from Animal Diabetes IV. Biennial Review Volume: 1992. London: Smith-Gordon; 1993:145-163.
6. Robison WG Jr, Laver NM, Lou MF. The role of aldose reductase in diabetic retinopathy: Prevention and intervention studies. In: Osborne NN, Chader GJ, eds. Progress in Retinal and Eye Research. Vol. 14. Oxford, Pergamon; 1995:593-640.
7. Kern TS, Engerman RL. Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci. 1995; 36:490-496.
8. Chiou S-H, Chylack LT Jr, Bunn HF, Kinoshita JH. Role of nonenzymatic glycosylation in experimental cataract formation. Biochem Biophys Res Comm. 1980; 95:894-901.
9. Kinoshita JH, Kador P, Datiles M. Aldose reductase in diabetic cataracts. JAMA. 1981;246:257-261.
10. Siḿan CM, Naeser P, Eriksson UJ. Increased lenticular aldose reductase activity and high incidence of congenital cataract in the offspring of diabetic rats. Acta Ophthalmol. 1993;71:629-636.
11. Lee AYW, Chung SK, Chung SSM. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA. 1995;92:2780-2784.
12. Simard-Duquesne N, Greselin E, Gonzalez R, Dvornik D. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat (42048). Proc Soc Exp Biol Med. 1985;178:599-605.
13. Dvornik D, Millen J, Hicks D, Cayen M, Sredy J. The pharmacokinetics of aldose reductase inhibitors. In: Sakamoto N, Kinoshita JH, Kador PF, Hotta N, eds. Polyol Pathway and Its Role in Diabetic Complications. Amsterdam: Elsevier Science; 1988:61-71.
14. Dvornik D, Millen J, Hicks DR, Kraml M. Tolrestat pharmacokinetics in rat peripheral nerve. J Diabetes Complications. 1994;8:18-26.
15. Sima AAF, Greene DA, Brown MB, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diabetes Complications. 1993;7:157-169.
16. Akagi Y, Kador PF, Kuwabara T, Kinoshita JH. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci. 1983;24:1516-1519.
17. Kern TS, Engerman RL. Hexitol production by canine retinal microvessels. Invest Ophthalmol Vis Sci. 1985; 26:382-384.
18. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318:1315-1321.
19. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetic complications: Biochemical basis and prospects for therapeutic intervention. Diabetes Rev. 1995;3:258-268.
20. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 1995;44:824-829.
21. Hammes H-P, Ali SS, Uhlmann M, et al. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia. 1995;38:269-273.
22. Sato S, Kador PF. NADPH-dependent reductases of the dog lens. Exp Eye Res. 1990;50:629-634.
23. Urbanowski JC, Cohenford MA, Dain JA. Nonenzymatic galactosylation of human serum albumin. In vitro preparation, J Biol Chem. 1982;257:111-115.
24. Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: Possible evolutionary significance. Science. 1981;213:222-224.
25. Malamas MS, Hohman TC, Millen J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[ (4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H),3'-pyrrolidine] -1,2',3,5'(2H)-tetrone and congeners. J Med Chem. 1994;37:2043-2058.
26. Bergmeyer HU, Bernt E, Schmidt F, Stork H. D-glucose: Determination with hexokinase and glucose-6-phosphate dehydrogenase. In: Methods of Enzymatic Analysis. 2nd ed. New York: Academic Press; 1974:1196-1201.
27. Guerrant GO, Moss CW. Determination of monosaccharides as aldonitrile O-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem. 1984;56:633-638.
28. Van Kampen EJ, Zijlstra WG. Standardization of hemoglobinometry: II: The hemoglobincyanide method. Clin Chim Acta. 1961;6:538-544.
29. Laver NM, Robison WG Jr, Pfeffer BA. Novel procedures for isolating intact retinal vascular beds from diabetic humans and animal models. Invest Ophthalmol Vis Sci. 1993;34:2097-2104.
30. Robison WG Jr, Laver NM, Jacot JL, Glover JP. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model. Invest Ophthalmol Vis Sci. 1995; 36:2368-2380.
31. Robison WG Jr, Kador PF, Akagi Y, Kinoshita JH, Gonzalez R, Dvornik D. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes. 1986; 35:295-299.
32. Robison WG Jr, Nagata M, Kinoshita JH. Aldose reductase and retinal capillary basement membrane thickening. Exp Eye Res. 1988;46:343-348.
33. Kojima K, Matsubara H, Harada T, et al. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats. Jpn J Ophthalmol. 1985;29:99-109.
34. Kador PF, Takahashi Y, Sato S, Wyman M. Amelioration of diabetes-like retinal changes in galactose-fed dogs. Preventive Med. 1994;23:717-721.
35. Robison WG Jr. Aldose reductase inhibition and retinopathy. Diabetes. 1994;43:337-338.
36. Robison WG Jr. Diabetic retinopathy: Galactose-fed rat model. Invest Ophthalmol Vis Sci. 1995;36:4A-1743. Letter.
37. Siperstein MD, Unger RH, Madison LL. Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest. 1968;47:1973-1999.